MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

NCT06747936 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-02-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia

Conditions

  • Primary Hypercholesterolemia

Interventions

DRUG

AD-2282

PO, Once daily, 8weeks

DRUG

Placebo of AD-2282

PO, Once daily, 8weeks

DRUG

AD-2281

PO, Once daily, 8weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2025-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06747936 on ClinicalTrials.gov